Russian Journal of Skin and Venereal DiseasesRussian Journal of Skin and Venereal DiseasesРоссийский журнал кожных и венерических болезней1560-95882412-9097Eco-Vector67791410.17816/dv677914KGDMDUDERMATOLOGYДЕРМАТОЛОГИЯReview ArticleTherapeutic potential of prostaglandins in dermatology: focus on vitiligoТерапевтический потенциал простагландинов в дерматологии: фокус на витилигоhttps://orcid.org/0009-0002-3741-66198308-7621DjahaiaElizaveta Yu.ДжахаяЕлизавета Юрьевна
Russian Federation
elizaveta_djahaia@mail.ruhttps://orcid.org/0000-0002-1172-96954743-6244KryuchkovaKira Yu.КрючковаКира Юрьевна
Russian Federation
kira.kruchkova@mail.ruhttps://orcid.org/0000-0003-0301-737X4391-9553KayumovaLyailya N.КаюмоваЛяиля Наилевна
Russian Federation

MD, Cand. Sci. (Medicine), Assistant Professor

канд. мед. наук, доцент

avestohka2005@inbox.ruhttps://orcid.org/0000-0001-7660-79582054-1086SmirnovKonstantin V.СмирновКонстантин Викторович
Russian Federation

MD, Cand. Sci. (Medicine)

канд. мед. наук

puva3@mail.ruhttps://orcid.org/0000-0002-4580-61934784-9730LomonosovKonstantin M.ЛомоносовКонстантин Михайлович
Russian Federation

MD, Dr. Sci. (Medicine), Professor

д-р мед. наук, профессор

lamclinic@yandex.ruThe First Sechenov Moscow State Medical University (Sechenov University)Первый Московский государственный медицинский университет имени И.М. Сеченова (Сеченовский Университет)22092025011120252844985063103202517082025Copyright ©; 2025, Eco-VectorCopyright ©; 2025, Эко-Вектор2025Eco-VectorЭко-Векторhttps://rjsvd.com/1560-9588/article/view/677914

This article presents an analysis of the therapeutic potential of prostaglandins in dermatology, with an emphasis on their application in vitiligo.

Prostaglandins are a group of low-molecular-weight lipid eicosanoids capable of regulating numerous physiological processes, including renal function, platelet aggregation, neurotransmitter release, and immune system activity, as well as influencing the skin, gastrointestinal tract, and reproductive system. The ubiquitous presence of prostaglandins in body tissues and their involvement in the regulation of inflammatory, regenerative, and proliferative processes make these molecules a promising subject for dermatological research.

The therapeutic potential of prostaglandins in dermatology extends far beyond their initial indications. Due to their unique properties, prostaglandins exert a complex effect: on the one hand, they activate melanocytes and stimulate melanogenesis; on the other hand, they modulate immune responses by suppressing autoimmune reactions. This article provides a detailed examination of the mechanisms of action of prostaglandins, including their role in inflammation regulation and their interaction with receptors in the skin. The advantages of prostaglandins in combination therapy for vitiligo are discussed, particularly in conjunction with phototherapy, microneedling, and laser-based methods. The article presents data demonstrating the high efficacy of prostaglandins in treating vitiligo, especially in resistant forms of the disease. The authors emphasize that prostaglandin-based therapy may significantly enhance vitiligo treatment outcomes by increasing repigmentation stability and providing more sustained results. The article also highlights the need for further research to optimize dosing regimens, treatment protocols, and duration of prostaglandin therapy.

This review article is based on a systematic search of scientific data (original research, clinical studies, reviews, and guidelines) reflecting current insights into the role of prostaglandins in dermatology and their therapeutic potential in vitiligo over 1987 to 2025 from PubMed, Scopus, Web of Science, and eLibrary.ru.

Статья посвящена анализу терапевтических возможностей простагландинов в дерматологии с акцентом на их применение при витилиго.

Простагландины представляют собой группу липидных низкомолекулярных эйкозаноидов, способных регулировать многочисленные процессы в организме, в частности функцию почек, агрегацию тромбоцитов, высвобождение нейромедиаторов и деятельность иммунной системы, а также оказывать влияние на кожу, желудочно-кишечный тракт, репродуктивную систему. Повсеместное присутствие простагландинов в тканях организма и их участие в регуляции воспалительных, регенеративных и пролиферативных процессах делают эти молекулы перспективным объектом для дерматологических исследований.

Терапевтические возможности простагландинов в дерматологии выходят далеко за рамки их исходных показаний. Благодаря своим уникальным свойствам простагландины оказывают комплексное влияние: с одной стороны, активируют меланоциты и стимулируют процессы меланогенеза, с другой ― модулируют иммунный ответ, подавляя аутоиммунные реакции. В статье подробно исследуются механизмы действия простагландинов, включая их роль в регуляции воспаления и взаимодействие с рецепторами в коже. Рассматриваются преимущества использования простагландинов в комбинированной терапии витилиго, в частности, в сочетании с фототерапией, микронидлингом и лазерными методами. Представлены данные о высокой эффективности простагландинов в лечении витилиго, особенно резистентных форм заболевания. В работе подчёркивается, что использование простагландинов может значительно улучшить эффективность лечения витилиго, увеличив устойчивость к репигментации и обеспечив более стабильные результаты. Авторы акцентируют также внимание на необходимости проведения дополнительных исследований для оптимизации дозировок, схем и продолжительности терапии простагландинами.

Для подготовки настоящей обзорной статьи проведён систематизированный поиск научной литературы (оригинальные статьи, клинические исследования, обзоры и рекомендации), отражающей современные представления о роли простагландинов в дерматологии и их терапевтическом потенциале при витилиго, за период с 1987 по 2025 год в базах данных PubMed, Scopus, Web of Science и eLibrary.ru.

prostaglandinsvitiligomelanocytesphototherapymicroneedlinglatanoprostbimatoprostPGE2PGF2αпростагландинывитилигомеланоцитыфототерапиямикронидлинглатанопростбиматопростPGE2PGF2αYanes DA, Mosser-Goldfarb JL. Emerging therapies for atopic dermatitis: the prostaglandin/leukotriene pathway. J Am Acad Dermatol. 2018;78(3 Suppl 1):S71–S75. doi: 10.1016/j.jaad.2017.12.021Harris SG, Padilla J, Koumas L, et al. Prostaglandins as modulators of immunity. Trends Immunol. 2002;23(3):144–150. doi: 10.1016/s1471-4906(01)02154-8Oyesola OO, Tait Wojno ED. Prostaglandin regulation of type 2 inflammation: from basic biology to therapeutic interventions. Eur J Immunol. 2021;51(10):2399–2416. doi: 10.1002/eji.202048909Ricciotti E, Fitzgerald GA. Prostaglandins and inflammation. Arterioscler Thromb Vasc Biol. 2011;31(5):986–1000. doi: 10.1161/ATVBAHA.110.207449Cheng H, Huang H, Guo Z, et al. Role of prostaglandin E2 in tissue repair and regeneration. Theranostics. 2021;11(18):8836–8854. doi: 10.7150/thno.63396Yasukawa K, Okuno T, Yokomizo T. Eicosanoids in skin wound healing. Int J Mol Sci 2020;21(22):8435. doi: 10.3390/ijms21228435Wautier JL, Wautier MP. Pro- and Anti-inflammatory prostaglandins and cytokines in humans: a mini review. Int J Mol Sci. 2023;24(11):9647. doi: 10.3390/ijms24119647Bull HA, Dowd PM. Prostaglandins, interleukins, and cutaneous inflammation. Immunomethods. 1993;2(3):219–226. doi: 10.1006/immu.1993.1025Calabrese L, Fiocco Z, Satoh TK, et al. Therapeutic potential of targeting interleukin-1 family cytokines in chronic inflammatory skin diseases. Br J Dermatol. 2022;186(6):925–941. doi: 10.1111/bjd.20975Honda T, Kabashima K. Prostanoids in allergy. Allergol Int. 2015;64(1):11–16. doi: 10.1016/j.alit.2014.08.002Hensby CN, Shroot B, Schaefer H, et al. Prostaglandins in human skin disease. Br J Dermatol. 1983;109(Suppl 25):22–25. doi: 10.1111/j.1365-2133.1983.tb06813.xAlestas T, Ganceviciene R, Fimmel S, et al. Enzymes involved in the biosynthesis of leukotriene B4 and prostaglandin E2 are active in sebaceous glands. J Mol Med (Berl). 2006;84(1):75–87. doi: 10.1007/s00109-005-0715-8Altman K, Chang C. Pathogenic intracellular and autoimmune mechanisms in urticaria and angioedema. Clin Rev Allergy Immunol. 2013;45(1):47–62. doi: 10.1007/s12016-012-8326-yGreaves MW, McDonald-Gibson W. Itch: role of prostaglandins. Br Med J. 1973;3(5881):608–609. doi: 10.1136/bmj.3.5881.608Lovell CR, Burton PA, Duncan EH, Burton JL. Prostaglandins and pruritus. Br J Dermatol. 1976;94(3):273–275. doi: 10.1111/j.1365-2133.1976.tb04383.xNagai H. Prostaglandin as a target molecule for pharmacotherapy of allergic inflammatory diseases. Allergol Int. 2008;57(3):187–196. doi: 10.2332/allergolint.R-08-161Shiraishi N, Nomura T, Tanizaki H, et al. Prostaglandin E2-EP3 axis in fine-tuning excessive skin inflammation by restricting dendritic cell functions. PLoS One. 2013;8(7):e69599. doi: 10.1371/journal.pone.0069599Angeli V, Staumont D, Charbonnier AS, et al. Activation of the D prostanoid receptor 1 regulates immune and skin allergic responses. J Immunol. 2004;172(6):3822–3829. doi: 10.4049/jimmunol.172.6.3822Sarashina H, Tsubosaka Y, Omori K, et al. Opposing immunomodulatory roles of prostaglandin D2 during the progression of skin inflammation. J Immunol. 2014;192(1):459–465. doi: 10.4049/jimmunol.1302080Cordeiro MF, Gandolfi S, Gugleta K, et al. How latanoprost changed glaucoma management. Acta Ophthalmol. 2024;102(2):e140–e155. doi: 10.1111/aos.15725Bakker R, Pierce S, Myers D. The role of prostaglandins E1 and E2, dinoprostone, and misoprostol in cervical ripening and the induction of labor: a mechanistic approach. Arch Gynecol Obstet. 2017;296(2):167–179. doi: 10.1007/s00404-017-4418-5Chiba T, Kashiwagi K, Kogure S, et al. Iridial pigmentation induced by latanoprost ophthalmic solution in Japanese glaucoma patients. J Glaucoma. 2001;10(5):406–410. doi: 10.1097/00061198-200110000-00008Alexander CL, Miller SJ, Abel SR. Prostaglandin analog treatment of glaucoma and ocular hypertension. Ann Pharmacother. 2002;36(3):504–511. doi: 10.1345/aph.1A178Inoue K, Shiokawa M, Higa R, et al. Adverse periocular reactions to five types of prostaglandin analogs. Eye (Lond). 2012;26(11):1465–1472. doi: 10.1038/eye.2012.195Carruthers J, Beer K, Carruthers A, et al. Bimatoprost 0.03% for the treatment of eyebrow hypotrichosis. Dermatol Surg. 2016;42(5):608–617. doi: 10.1097/DSS.0000000000000755Beer KR, Julius H, Dunn M, Wilson F. Treatment of eyebrow hypotrichosis using bimatoprost: a randomized, double-blind, vehicle-controlled pilot study. Dermatol Surg. 2013;39(7):1079–1087. doi: 10.1111/dsu.12199Yoelin SG, Fagien S, Cox SE, et al. A retrospective review and observational study of outcomes and safety of bimatoprost ophthalmic solution 0.03% for treating eyelash hypotrichosis. Dermatol Surg. 2014;40(10):1118–1124. doi: 10.1097/01.DSS.0000452658.83001.d9Blume-Peytavi U, Lönnfors S, Hillmann K, Garcia Bartels N. A randomized double-blind placebo-controlled pilot study to assess the efficacy of a 24-week topical treatment by latanoprost 0.1% on hair growth and pigmentation in healthy volunteers with androgenetic alopecia. J Am Acad Dermatol. 2012;66(5):794–800. doi: 10.1016/j.jaad.2011.05.026Renert-Yuval Y, Guttman-Yassky E. The changing landscape of alopecia areata: the therapeutic paradigm. Adv Ther. 2017;34(7):1594–1609. doi: 10.1007/s12325-017-0542-7Levy LL, Emer JJ. Female pattern alopecia: current perspectives. Int J Womens Health. 2013;5:541–556. doi: 10.2147/IJWH.S49337Barrón-Hernández YL, Tosti A. Bimatoprost for the treatment of eyelash, eyebrow and scalp alopecia. Expert Opin Investig Drugs. 2017;26(4):515–522. doi: 10.1080/13543784.2017.1303480Barton VR, Toussi A, Awasthi S, Kiuru M. Treatment of pediatric alopecia areata: a systematic review. J Am Acad Dermatol. 2021;86(6):1318–1334. doi: 10.1016/j.jaad.2021.04.077Nashan D, Nieschlag E. Male androgenetic alopecia. In: Andrology. First online: 27 October 2023. P. 491–499. doi: 10.1007/978-3-031-31574-9_33Eriksson L, Lindström B, Ekenberg L. Patients’ experiences of telerehabilitation at home after shoulder joint replacement. J Telemed Telecare. 2011;17(1):25–30. doi: 10.1258/jtt.2010.100317De Caridi G, Massara M, Stilo F, et al. Effectiveness of prostaglandin E1 in patients with mixed arterial and venous ulcers of the lower limbs. Int Wound J. 2016;13(5):625–629. doi: 10.1111/iwj.12334Massaki AB, Fabi SG, Fitzpatrick R. Repigmentation of hypopigmented scars using an erbium-doped 1,550-nm fractionated laser and topical bimatoprost. Dermatologic Surg. 2012;38(7 Pt 1):995–1001. doi: 10.1111/j.1524-4725.2012.02389.xMatejka M, Nell A, Kment G, et al. Local benefit of prostaglandin E2 in radiochemotherapy-induced oral mucositis. Br J Oral Maxillofac Surg. 1990;28(2):89–91. doi: 10.1016/0266-4356(90)90128-8Porteder H, Rausch E, Kment G, et al. Local prostaglandin E2 in patients with oral malignancies undergoing chemo- and radiotherapy. J Craniomaxillofac Surg. 1988;16(8):371–374. doi: 10.1016/s1010-5182(88)80082-9Remy W, Sigl I, Leipold B. Prostaglandin E2 gel improvement of psoriatic lesions. Int J Dermatol. 1986;25(4):266–268. doi: 10.1111/j.1365-4362.1986.tb02240.xPathak GN, Tan IJ, Bai G, et al. Vitiligo: from mechanisms of disease to treatable pathways. Ski Heal Dis. 2024;4(6):e460. doi: 10.1002/ski2.460Marchioro HZ, Silva de Castro CC, Fava VM, et al. Update on the pathogenesis of vitiligo. An Bras Dermatol. 2022;97(4):478–490. doi: 10.1016/j.abd.2021.09.008Speeckaert R, Caelenberg E Van, Belpaire A, et al. Vitiligo: from pathogenesis to treatment. J Clin Med. 2024;13(17):5225. doi: 10.3390/jcm13175225Diotallevi F, Gioacchini H, De Simoni E, et al. Vitiligo, from pathogenesis to therapeutic advances: state of the art. Int J Mol Sci. 2023;24(5):4910. doi: 10.3390/ijms24054910Iwanowski T, Kołkowski K, Nowicki RJ, Sokołowska-Wojdyło M. Etiopathogenesis and emerging methods for treatment of vitiligo. Int J Mol Sci. 2023;24(11):9749. doi: 10.3390/ijms24119749Tomita Y, Iwamoto M, Masuda T, Tagami H. Stimulatory effect of prostaglandin E2 on the configuration of normal human melanocytes in vitro. J Invest Dermatol. 1987;89(3):299–301. doi: 10.1111/1523-1747.ep12471536Nordlund JJ, Collins CE, Rheins LA. Prostaglandin E2 and D2 but not MSH stimulate the proliferation of pigment cells in the pinnal epidermis of the DBA/2 mouse. J Invest Dermatol. 1986;86(4):433–437. doi: 10.1111/1523-1747.ep12285717Pourriyahi H, Hosseini NS, Nooshabadi MP, et al. Utility of prostaglandin analogues and phosphodiesterase inhibitors as promising last resorts for the treatment of vitiligo: a systematic review, from mechanisms of action to mono-, combination and comparative therapies. J Cosmet Dermatol. 2024;23(11):3466–3487. doi: 10.1111/jocd.16468Kim JY, Shin JY, Kim MR, et al. siRNA-mediated knock-down of COX-2 in melanocytes suppresses melanogenesis. Exp Dermatol. 2012;21(6):420–425. doi: 10.1111/j.1600-0625.2012.01483.xNeinaa YM, Mahmoud MA, El Maghraby GM, Ibrahim ZA. Efficacy of prostaglandin E2 versus prostaglandin F2 alpha assisted with narrowband-UVB in stable vitiligo. Arch Dermatol Res. 2023;315(9):2647–2653. doi: 10.1007/s00403-023-02700-8Scott G, Leopardi S, Printup S, et al. Proteinase-activated receptor-2 stimulates prostaglandin production in keratinocytes: analysis of prostaglandin receptors on human melanocytes and effects of PGE2 and PGF2alpha on melanocyte dendricity. J Invest Dermatol. 2004;122(5):1214–1224. doi: 10.1111/j.0022-202X.2004.22516.xSoontrapa K, Honda T, Sakata D, et al. Prostaglandin E2-prostoglandin E receptor subtype 4 (EP4) signaling mediates UV irradiation-induced systemic immunosuppression. Proc Natl Acad Sci USA. 2011;108(16):6668–6673. doi: 10.1073/pnas.1018625108Fu C, Chen J, Lu J, et al. Roles of inflammation factors in melanogenesis (Review). Mol Med Rep. 2020;21(3):1421–1430. doi: 10.3892/mmr.2020.10950Wollenberg A, Barbarot S, Bieber T, et al. Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part I. J Eur Acad Dermatology Venereol. 2018;32(5):657–682. doi: 10.1111/jdv.14891Oray M, Abu Samra K, Ebrahimiadib N, et al. Long-term side effects of glucocorticoids. Expert Opin Drug Saf. 2016;15(4):457–465. doi: 10.1517/14740338.2016.1140743Singh RK. Impact of Ultraviolet Light on Vitiligo. Adv Exp Med Biol. 2017;996:55–60. doi: 10.1007/978-3-319-56017-5_5Parsad D, Pandhi R, Dogra S, Kumar B. Topical prostaglandin analog (PGE2) in vitiligo: a preliminary study. Int J Dermatol. 2002;41(12):942–945. doi: 10.1046/j.1365-4362.2002.01612.xKapoor R, Phiske MM, Jerajani HR. Evaluation of safety and efficacy of topical prostaglandin E2 in treatment of vitiligo. Br J Dermatol. 2009;160(4):861–863. doi: 10.1111/j.1365-2133.2008.08923.xAnbar TS, El-Ammawi TS, Abdel-Rahman AT, Hanna MR. The effect of latanoprost on vitiligo: a preliminary comparative study. Int J Dermatol. 2015;54(5):587–593. doi: 10.1111/ijd.12631Korobko IV, Lomonosov KM. A pilot comparative study of topical latanoprost and tacrolimus in combination with narrow-band ultraviolet B phototherapy and microneedling for the treatment of nonsegmental vitiligo. Dermatol Ther. 2016;29(6):437–441. doi: 10.1111/dth.12383Neinaa YM, Lotfy SS, Ghaly NR, Doghaim NN. A comparative study of combined microneedling and narrowband ultraviolet B phototherapy versus their combination with topical latanoprost in the treatment of vitiligo. Dermatol Ther. 2021;34(2):e14813. doi: 10.1111/dth.14813Fawzy M, Al-Mokadem S, Alshereef M, Elkholy B. Narrowband ultraviolet B phototherapy combined with intralesional injection of either latanoprost or platelet-rich plasma for stable nonsegmental vitiligo. Photodermatol Photoimmunol Photomed. 2024;40(1):e12929. doi: 10.1111/phpp.12929Eldelee SA, Gheida SF, Sarhan NI, et al. Evaluation of the effect of combined intralesional injection of prostaglandin F2α with narrow band UVB phototherapy in treatment of resistant cases of vitiligo. J Dermatolog Treat. 2021;32(4):383–390. doi: 10.1080/09546634.2019.1658860Kanokrungsee S, Khunkhet S, Rojhirunsakool S, et al. Triple combination therapy of narrowband ultraviolet B, fractional carbon dioxide laser and topical bimatoprost 0.01% for non-segmental vitiligo on non-facial areas: a randomized half-body, double-blind, placebo-controlled, comparative study. Dermatol Ther. 2022;35(1):e15198. doi: 10.1111/dth.15198Omar SS, Elmulla KF, Aly RG, et al. A triple combination of latanoprost, fractional CO2 laser, and platelet-rich plasma in localized vitiligo: a clinical and histopathologic study. Photodermatol Photoimmunol Photomed. 2024;40(1):e12944. doi: 10.1111/phpp.12944Zaky MS, Atallah RB, El Abasy NT, Elsaie ML. Comparative study between efficacy of Excimer light with topical Tacrolimus 0.1% versus excimer light with topical Bimatoprost 0.01% in treatment of facial Vitiligo. Arch Dermatol Res. 2024;316(7):350. doi: 10.1007/s00403-024-03054-5Ghiasi M, Isazade A, Marhamati T, et al. The efficacy of 308-nm excimer laser with topicalbimatoprost 0.03% for facial vitiligo. J Cosmet Dermatol. 2025;24(2):e70020. doi: 10.1111/jocd.70020